{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:09:00Z","timestamp":1788473340236,"version":"build-2803163510"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-024-05734-x","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T04:25:16Z","timestamp":1732249516000},"page":"2757-2794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety, efficacy, and immunogenicity of SARS-CoV-2 mRNA vaccination in children and adult patients with rheumatic diseases: a comprehensive literature review"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9099-1849","authenticated-orcid":false,"given":"Preeti","family":"Dhanasekaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4574-6512","authenticated-orcid":false,"given":"Biraveena Thirunavuc","family":"Karasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4688-7829","authenticated-orcid":false,"given":"Anselm","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"5734_CR1","unstructured":"World Health Organization Coronavirus COVID-19 Dashboard. https:\/\/covid19.who.int\/. Accessed 20 Dec 2023"},{"issue":"12","key":"5734_CR2","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/s41562-020-01009-0","volume":"4","author":"N Haug","year":"2020","unstructured":"Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, Klimek P (2020) Ranking the effectiveness of worldwide COVID-19 government interventions. Nat Hum Behav 4(12):1303\u20131312. https:\/\/doi.org\/10.1038\/s41562-020-01009-0","journal-title":"Nat Hum Behav"},{"key":"5734_CR3","doi-asserted-by":"publisher","unstructured":"Ferorelli D, Mandarelli G, Solarino B (2020) Ethical challenges in health care policy during COVID-19 pandemic in Italy. Medicina 56(12). https:\/\/doi.org\/10.3390\/medicina56120691","DOI":"10.3390\/medicina56120691"},{"issue":"23","key":"5734_CR4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1212\/wnl.0000000000009520","volume":"94","author":"SYH Kim","year":"2020","unstructured":"Kim SYH, Grady C (2020) Ethics in the time of COVID: what remains the same and what is different. Neurology 94(23):1007\u20131008. https:\/\/doi.org\/10.1212\/wnl.0000000000009520","journal-title":"Neurology"},{"key":"5734_CR5","unstructured":"Crist C (2022) Omicron subvariant 1.5 times more contagious than Omicron. WebMD. Retrieved 20 Dec 2022, from https:\/\/www.webmd.com\/lung\/news\/20220130\/omicron-subvariant-more-contagious-than-omicron"},{"key":"5734_CR6","doi-asserted-by":"publisher","first-page":"m4857","DOI":"10.1136\/bmj.m4857","volume":"371","author":"J Wise","year":"2020","unstructured":"Wise J (2020) Covid-19: New coronavirus variant is identified in UK. BMJ 371:m4857. https:\/\/doi.org\/10.1136\/bmj.m4857","journal-title":"BMJ"},{"issue":"5","key":"5734_CR7","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1002\/jmv.27588","volume":"94","author":"Y Araf","year":"2022","unstructured":"Araf Y, Akter F, Tang YD, Fatemi R, Parvez MSA, Zheng C, Hossain MG (2022) Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol 94(5):1825\u20131832. https:\/\/doi.org\/10.1002\/jmv.27588","journal-title":"J Med Virol"},{"key":"5734_CR8","doi-asserted-by":"publisher","unstructured":"Bloom DE, Fan VY, Sevilla JP (2018) The broad socioeconomic benefits of vaccination. Sci Transl Med 10(441):eaaj2345. https:\/\/doi.org\/10.1126\/scitranslmed.aaj2345","DOI":"10.1126\/scitranslmed.aaj2345"},{"issue":"1","key":"5734_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-021-01311-z","volume":"20","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X (2021) mRNA vaccine: a potential therapeutic strategy. Mol Cancer 20(1):33. https:\/\/doi.org\/10.1186\/s12943-021-01311-z","journal-title":"Mol Cancer"},{"key":"5734_CR10","doi-asserted-by":"publisher","unstructured":"Tselis A, Booss J (2014) Viral vaccines and antiviral therapy. Encycl Neurol Sci 659\u2013669. https:\/\/doi.org\/10.1016\/B978-0-12-385157-4.00389-4","DOI":"10.1016\/B978-0-12-385157-4.00389-4"},{"key":"5734_CR11","unstructured":"Vaccines and Related Biological Products Advisory Committee Meeting. FDA Briefing Document. Pfizer-BioNTech COVID-19 Vaccine, December 10, 2020, pp 1\u201353"},{"issue":"27","key":"5734_CR12","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Gruber WC (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"key":"5734_CR13","unstructured":"Vaccines and Related Biological Products Advisory Committee Meeting. FDA Briefing Document. Moderna COVID-19 Vaccine, December 17, 2020, pp 1\u201354"},{"issue":"9","key":"5734_CR14","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/14760584.2017.1355245","volume":"16","author":"C Iavarone","year":"2017","unstructured":"Iavarone C, O\u2019Hagan DT, Yu D, Delahaye NF, Ulmer JB (2017) Mechanism of action of mRNA-based vaccines. Expert Rev Vaccines 16(9):871\u2013881. https:\/\/doi.org\/10.1080\/14760584.2017.1355245","journal-title":"Expert Rev Vaccines"},{"key":"5734_CR15","unstructured":"U.S. Food and Drug Administration Pfizer-BioNTech COVID-19 Vaccines, Comirnaty, Pfizer-BioNTech COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, Bivalent. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/pfizer-biontech-covid-19-vaccines. Accessed 15 Jan 2023"},{"issue":"4","key":"5734_CR16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","volume":"14","author":"TLW Muskardin","year":"2018","unstructured":"Muskardin TLW, Niewold TB (2018) Type I interferon in rheumatic diseases. Nat Rev Rheumatol 14(4):214\u2013228. https:\/\/doi.org\/10.1038\/nrrheum.2018.31","journal-title":"Nat Rev Rheumatol"},{"key":"5734_CR17","doi-asserted-by":"publisher","first-page":"108765","DOI":"10.1016\/j.clim.2021.108765","volume":"229","author":"PA Ntouros","year":"2021","unstructured":"Ntouros PA, Vlachogiannis NI, Pappa M, Nezos A, Mavragani CP, Tektonidou MG, Sfikakis PP (2021) Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus systemic lupus erythematosus. Clin Immunol 229:108765. https:\/\/doi.org\/10.1016\/j.clim.2021.108765","journal-title":"Clin Immunol"},{"key":"5734_CR18","doi-asserted-by":"publisher","unstructured":"Souliotis VL, Vlachogiannis NI, Pappa M, Argyriou A, Ntouros PA, Sfikakis PP (2019) DNA damage response and oxidative stress in systemic autoimmunity. Int J Mol Sci 21(1):55. https:\/\/doi.org\/10.3390\/ijms21010055","DOI":"10.3390\/ijms21010055"},{"issue":"1","key":"5734_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/art.41924","volume":"74","author":"CM Connolly","year":"2022","unstructured":"Connolly CM, Ruddy JA, Boyarsky BJ, Barbur I, Werbel WA, Geetha D, Paik JJ (2022) Disease flare and reactogenicity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination. Arthritis Rheumatol 74(1):28\u201332. https:\/\/doi.org\/10.1002\/art.41924","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"5734_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/annrheumdis-2021-221490","volume":"81","author":"PM Machado","year":"2022","unstructured":"Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, Mariette X (2022) Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR coronavirus vaccine (COVAX) physician-reported registry. Ann Rheum Dis 81(5):695\u2013709. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221490","journal-title":"Ann Rheum Dis"},{"key":"5734_CR21","doi-asserted-by":"publisher","unstructured":"Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, Sparks JA (2021) Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 7(3). https:\/\/doi.org\/10.1136\/rmdopen-2021-001814","DOI":"10.1136\/rmdopen-2021-001814"},{"issue":"5","key":"5734_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Zaks T (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384(5):403\u2013416. https:\/\/doi.org\/10.1056\/NEJMoa2035389","journal-title":"N Engl J Med"},{"issue":"11","key":"5734_CR23","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1080\/21645515.2021.1958611","volume":"17","author":"T Ko","year":"2021","unstructured":"Ko T, Dendle C, Woolley I, Morand E, Antony A (2021) SARS-COV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study. Hum Vaccin Immunother 17(11):4048\u20134056. https:\/\/doi.org\/10.1080\/21645515.2021.1958611","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"5734_CR24","doi-asserted-by":"publisher","first-page":"e241","DOI":"10.1016\/s2665-9913(21)00037-0","volume":"3","author":"L Boekel","year":"2021","unstructured":"Boekel L, Hooijberg F, van Kempen ZLE, Vogelzang EH, Tas SW, Killestein J, Wolbink GJ (2021) Perspective of patients with autoimmune diseases on COVID-19 vaccination. Lancet Rheumatol 3(4):e241\u2013e243. https:\/\/doi.org\/10.1016\/s2665-9913(21)00037-0","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"5734_CR25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/annrheumdis-2021-221571","volume":"81","author":"X Li","year":"2022","unstructured":"Li X, Tong X, Yeung WWY, Kuan P, Yum SHH, Chui CSL, Wong ICK (2022) Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis 81(4):564\u2013568. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221571","journal-title":"Ann Rheum Dis"},{"key":"5734_CR26","doi-asserted-by":"publisher","unstructured":"Rider LG, Parks CG, Wilkerson J, Schiffenbauer AI, Kwok RK, Noroozi Farhadi P, Miller FW (2022) Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology 61(Si2):Si143\u2013si150. https:\/\/doi.org\/10.1093\/rheumatology\/keac249","DOI":"10.1093\/rheumatology\/keac249"},{"issue":"2","key":"5734_CR27","doi-asserted-by":"publisher","first-page":"e002417","DOI":"10.1136\/rmdopen-2022-002417","volume":"8","author":"SW Syversen","year":"2022","unstructured":"Syversen SW, Jyssum I, Tveter AT, Sexton J, Christensen IE, Tran TT, Goll GL (2022) Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy. RMD Open 8(2):e002417. https:\/\/doi.org\/10.1136\/rmdopen-2022-002417","journal-title":"RMD Open"},{"key":"5734_CR28","doi-asserted-by":"publisher","unstructured":"Nakafero G, Grainge MJ, Card T, Mallen CD, Nguyen Van-Tam JS, Williams HC, Abhishek A (2022) Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keac484","DOI":"10.1093\/rheumatology\/keac484"},{"issue":"6","key":"5734_CR29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00296-022-05119-y","volume":"42","author":"A Ozdede","year":"2022","unstructured":"Ozdede A, Guner S, Ozcifci G, Yurttas B, Toker Dincer Z, Atli Z, Seyahi E (2022) Safety of SARS-CoV-2 vaccination in patients with Behcet\u2019s syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine. Rheumatol Int 42(6):973\u2013987. https:\/\/doi.org\/10.1007\/s00296-022-05119-y","journal-title":"Rheumatol Int"},{"issue":"4","key":"5734_CR30","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mus.27681","volume":"66","author":"A Gil-Vila","year":"2022","unstructured":"Gil-Vila A, Ravichandran N, Selva-O\u2019Callaghan A, Sen P, Nune A, Gaur PS, Gupta L (2022) COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety in idiopathic inflammatory myopathies. Muscle Nerve 66(4):426\u2013437. https:\/\/doi.org\/10.1002\/mus.27681","journal-title":"Muscle Nerve"},{"issue":"2","key":"5734_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1001\/jamainternmed.2021.7024","volume":"182","author":"Sun, J., Zheng, Q., Madhira, V., Olex, A. L., Anzalone, A. J., Vinson, A., Consortium, N. C. C. C","year":"2022","unstructured":"Sun, J., Zheng, Q., Madhira, V., Olex, A. L., Anzalone, A. J., Vinson, A., Consortium, N. C. C. C (2022) Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med 182(2):153\u2013162. https:\/\/doi.org\/10.1001\/jamainternmed.2021.7024","journal-title":"JAMA Intern Med"},{"issue":"12","key":"5734_CR32","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/art.42287","volume":"74","author":"CM Calabrese","year":"2022","unstructured":"Calabrese CM, Kirchner E, Husni EM, Moss BP, Fernandez AP, Jin Y, Calabrese LH (2022) Breakthrough SARS-CoV-2 infections in patients with immune-mediated disease undergoing B cell-depleting therapy: a retrospective cohort analysis. Arthritis Rheumatol 74(12):1906\u20131915. https:\/\/doi.org\/10.1002\/art.42287","journal-title":"Arthritis Rheumatol"},{"key":"5734_CR33","doi-asserted-by":"publisher","first-page":"102959","DOI":"10.1016\/j.jaut.2022.102959","volume":"134","author":"M Ma","year":"2022","unstructured":"Ma M, Santosa A, Fong W, Chew LC, Low AH, Law A, Lahiri M (2022) Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING). J Autoimmun 134:102959. https:\/\/doi.org\/10.1016\/j.jaut.2022.102959","journal-title":"J Autoimmun"},{"key":"5734_CR34","doi-asserted-by":"publisher","unstructured":"Ziv A, Heshin-Bekenstein M, Haviv R, Kivity S, Netzer D, Yaron S, Schur Y, Egert T, Egert Y, Sela Y, Hashkes PJ, Uziel Y (2023) Effectiveness of the BNT162b2 mRNA COVID-19 vaccine among adolescents with juvenile-onset inflammatory rheumatic diseases. Rheumatology 62(SI2):SI145\u2013SI151. https:\/\/doi.org\/10.1093\/rheumatology\/keac408","DOI":"10.1093\/rheumatology\/keac408"},{"issue":"3","key":"5734_CR35","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1002\/iid3.589","volume":"10","author":"YK Li","year":"2022","unstructured":"Li YK, Lui MPK, Yam LL, Cheng CS, Tsang THT, Kwok WS, Chung HY (2022) COVID-19 vaccination in patients with rheumatic diseases: vaccination rates, patient perspectives, and side effects. Immun Inflamm Dis 10(3):e589. https:\/\/doi.org\/10.1002\/iid3.589","journal-title":"Immun Inflamm Dis"},{"key":"5734_CR36","doi-asserted-by":"publisher","unstructured":"Naveen R, Sen P, Griger Z, Day J, Joshi M, Nune A, Nikiphorou E, Saha S, Tan AL, Shinjo SK, Ziade N, Velikova T, Milchert M, Jagtap K, Parodis I, Edgar Gracia-Ramos A, Cavagna L, Kuwana M, Knitza J, Chen YM, Gupta L (2023) Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and 2 surveys. Rheumatology:kead180. Advance online publication. https:\/\/doi.org\/10.1093\/rheumatology\/kead180","DOI":"10.1093\/rheumatology\/kead180"},{"key":"5734_CR37","doi-asserted-by":"publisher","unstructured":"Sen P, Ravichandran N, Nune A, Lilleker JB, Agarwal V, Kardes S, Kim M, Day J, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Selva O\u2019Callaghan A, Nikiphorou E, Chatterjee T, Tan AL, Cavagna L, Saavedra MA, COVAD Study Group (2022) COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. Rheumatology 62(1):65\u201376. https:\/\/doi.org\/10.1093\/rheumatology\/keac305","DOI":"10.1093\/rheumatology\/keac305"},{"issue":"12","key":"5734_CR38","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1136\/ard-2022-222954","volume":"81","author":"Y Kawano","year":"2022","unstructured":"Kawano Y, Patel NJ, Wang X, Cook CE, Vanni KM, Kowalski EN, Banasiak EP, Qian G, DiIorio M, Hsu TY, Weinblatt ME, Todd DJ, Wallace ZS, Sparks JA (2022) Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. Ann Rheum Dis 81(12):1742\u20131749. https:\/\/doi.org\/10.1136\/ard-2022-222954","journal-title":"Ann Rheum Dis"},{"key":"5734_CR39","doi-asserted-by":"publisher","first-page":"102984","DOI":"10.1016\/j.jaut.2022.102984","volume":"135","author":"KPJ van Dam","year":"2023","unstructured":"van Dam KPJ, Wieske L, Stalman EW, Kummer LYL, Roosen J, van Kempen ZLE, Killestein J, Volkers AG, Boekel L, Wolbink GJ, van der Kooi AJ, Raaphorst J, L\u00f6wenberg M, Takkenberg RB, D\u2019Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, T2B! Immunity against SARS-CoV-2 study group (2023) Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations. J Autoimmun 135:102984. https:\/\/doi.org\/10.1016\/j.jaut.2022.102984","journal-title":"J Autoimmun"},{"issue":"1","key":"5734_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00296-022-05229-7","volume":"43","author":"Hoff, L. S., Ravichandran, N., Shinjo, S. K., Day, J., Sen, P., Junior, J. G., Lilleker, J. B., Joshi, M., Agarwal, V., Kardes, S., Kim, M., Milchert, M., Makol, A., Gheita, T., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, I., O\u2019Callaghan, A. S., Nikiphorou, E., COVAD Study Group","year":"2023","unstructured":"Hoff, L. S., Ravichandran, N., Shinjo, S. K., Day, J., Sen, P., Junior, J. G., Lilleker, J. B., Joshi, M., Agarwal, V., Kardes, S., Kim, M., Milchert, M., Makol, A., Gheita, T., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, I., O\u2019Callaghan, A. S., Nikiphorou, E., COVAD Study Group (2023) COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey. Rheumatol Int 43(1):47\u201358. https:\/\/doi.org\/10.1007\/s00296-022-05229-7","journal-title":"Rheumatol Int"},{"issue":"7","key":"5734_CR41","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/rheumatology\/keac661","volume":"62","author":"R Naveen","year":"2023","unstructured":"Naveen R, Nikiphorou E, Joshi M, Sen P, Lindblom J, Agarwal V, Lilleker JB, Tan AL, Salim B, Ziade N, Velikova T, Gracia-Ramos AE, Kuwana M, Day J, Makol A, Distler O, Chinoy H, Traboco LS, Wibowo SAK, Tehozol EAZ, Parodis I (2023) Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study. Rheumatology 62(7):2453\u20132463. https:\/\/doi.org\/10.1093\/rheumatology\/keac661","journal-title":"Rheumatology"},{"issue":"2","key":"5734_CR42","doi-asserted-by":"publisher","first-page":"e002322","DOI":"10.1136\/rmdopen-2022-002322","volume":"8","author":"S Lawson-Tovey","year":"2022","unstructured":"Lawson-Tovey S, Machado PM, Strangfeld A, Mateus E, Gossec L, Carmona L, Hyrich KL (2022) SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry. RMD Open 8(2):e002322. https:\/\/doi.org\/10.1136\/rmdopen-2022-002322","journal-title":"RMD Open"},{"issue":"1","key":"5734_CR43","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12969-022-00724-4","volume":"20","author":"C Udaondo","year":"2022","unstructured":"Udaondo C, C\u00e1mara C, Miguel Berenguel L, Alcobendas Rueda R, Mu\u00f1oz G\u00f3mez C, Mill\u00e1n Longo C, Calvo C (2022) Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases. Pediatr Rheumatol Online J 20(1):64. https:\/\/doi.org\/10.1186\/s12969-022-00724-4","journal-title":"Pediatr Rheumatol Online J"},{"issue":"6","key":"5734_CR44","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1080\/00325481.2022.2074700","volume":"134","author":"E Arslanoglu Aydin","year":"2022","unstructured":"Arslanoglu Aydin E, Baglan E, Bagrul I, Tuncez S, Ozdel S, Bulbul M (2022) Safety of COVID-19 vaccines and disease flares after vaccines in children with rheumatic disease. Postgrad Med 134(6):616\u2013621. https:\/\/doi.org\/10.1080\/00325481.2022.2074700","journal-title":"Postgrad Med"},{"key":"5734_CR45","doi-asserted-by":"publisher","unstructured":"Yoshida T, Tsuji H, Onishi A, Takase Y, Shirakashi M, Onizawa H, Morinobu A (2022) Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus. Lupus Sci Med 9(1). https:\/\/doi.org\/10.1136\/lupus-2022-000727","DOI":"10.1136\/lupus-2022-000727"},{"issue":"2","key":"5734_CR46","doi-asserted-by":"publisher","first-page":"e002460","DOI":"10.1136\/rmdopen-2022-002460","volume":"8","author":"F Carubbi","year":"2022","unstructured":"Carubbi F, Alunno A, Santilli J, Natali L, Mancini B, Di Gregorio N, Ferri C (2022) Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares. RMD Open 8(2):e002460. https:\/\/doi.org\/10.1136\/rmdopen-2022-002460","journal-title":"RMD Open"},{"issue":"11","key":"5734_CR47","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1093\/rheumatology\/keac105","volume":"61","author":"JG Yeo","year":"2022","unstructured":"Yeo JG, Chia WN, Teh KL, Book YX, Hoh SF, Gao X, Arkachaisri T (2022) Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseases. Rheumatology 61(11):4472\u20134481. https:\/\/doi.org\/10.1093\/rheumatology\/keac105","journal-title":"Rheumatology"},{"issue":"1","key":"5734_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00296-021-05039-3","volume":"42","author":"GE Fragoulis","year":"2022","unstructured":"Fragoulis GE, Bournia VK, Mavrea E, Evangelatos G, Fragiadaki K, Karamanakos A, Sfikakis PP (2022) COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study. Rheumatol Int 42(1):31\u201339. https:\/\/doi.org\/10.1007\/s00296-021-05039-3","journal-title":"Rheumatol Int"},{"issue":"11","key":"5734_CR49","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1093\/rheumatology\/keac103","volume":"61","author":"M Heshin-Bekenstein","year":"2022","unstructured":"Heshin-Bekenstein M, Ziv A, Toplak N, Hagin D, Kadishevich D, Butbul YA, Uziel Y (2022) Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. Rheumatology 61(11):4263\u20134272. https:\/\/doi.org\/10.1093\/rheumatology\/keac103","journal-title":"Rheumatology"},{"issue":"10","key":"5734_CR50","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","volume":"80","author":"UM Geisen","year":"2021","unstructured":"Geisen UM, Berner DK, Tran F, S\u00fcmb\u00fcl M, Vullriede L, Ciripoi M, Hoyer BF (2021) Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 80(10):1306\u20131311. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220272","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"5734_CR51","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","volume":"80","author":"V Furer","year":"2021","unstructured":"Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, Elkayam O (2021) Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 80(10):1330\u20131338. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220647","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5734_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13075-021-02674-w","volume":"24","author":"FR Spinelli","year":"2022","unstructured":"Spinelli FR, Favalli EG, Garufi C, Cornalba M, Colafrancesco S, Conti F, Caporali R (2022) Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine. Arthritis Res Ther 24(1):21. https:\/\/doi.org\/10.1186\/s13075-021-02674-w","journal-title":"Arthritis Res Ther"},{"key":"5734_CR53","doi-asserted-by":"publisher","unstructured":"Pinte L, Negoi F, Ionescu GD, Caraiola S, Balaban DV, Badea C, Baicus C (2021) COVID-19 vaccine does not increase the risk of disease flare-ups among patients with autoimmune and immune-mediated diseases. J Pers Med 11(12). https:\/\/doi.org\/10.3390\/jpm11121283","DOI":"10.3390\/jpm11121283"},{"issue":"12","key":"5734_CR54","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/acr.24894","volume":"74","author":"MM Yang","year":"2022","unstructured":"Yang MM, Taylor KE, Paez D, Carividi A, Demissie E, Pawar N, Gensler LS (2022) Reactogenicity of the messenger RNA SARS-CoV-2 vaccines associated with immunogenicity in patients with autoimmune and inflammatory disease. Arthritis Care Res 74(12):1953\u20131960. https:\/\/doi.org\/10.1002\/acr.24894","journal-title":"Arthritis Care Res"},{"issue":"10","key":"5734_CR55","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1136\/annrheumdis-2021-220503","volume":"80","author":"Y Braun-Moscovici","year":"2021","unstructured":"Braun-Moscovici Y, Kaplan M, Braun M, Markovits D, Giryes S, Toledano K, Balbir-Gurman A (2021) Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis 80(10):1317\u20131321. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220503","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5734_CR56","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/art.41937","volume":"74","author":"PM Izmirly","year":"2022","unstructured":"Izmirly PM, Kim MY, Samanovic M, Fernandez-Ruiz R, Ohana S, Deonaraine KK, Buyon JP (2022) Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination. Arthritis Rheumatol 74(2):284\u2013294. https:\/\/doi.org\/10.1002\/art.41937","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"5734_CR57","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/annrheumdis-2021-221097","volume":"81","author":"Q Moyon","year":"2022","unstructured":"Moyon Q, Sterlin D, Miyara M, Anna F, Mathian A, Lhote R, Amoura Z (2022) BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Ann Rheum Dis 81(4):575\u2013583. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221097","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5734_CR58","doi-asserted-by":"publisher","first-page":"e002187","DOI":"10.1136\/rmdopen-2021-002187","volume":"8","author":"J Liew","year":"2022","unstructured":"Liew J, Gianfrancesco M, Harrison C, Izadi Z, Rush S, Lawson-Tovey S, Yazdany J (2022) SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 global rheumatology alliance provider registry. RMD Open 8(1):e002187. https:\/\/doi.org\/10.1136\/rmdopen-2021-002187","journal-title":"RMD Open"},{"key":"5734_CR59","doi-asserted-by":"publisher","unstructured":"Tang W, Askanase AD, Khalili L, Merrill JT (2021) SARS-CoV-2 vaccines in patients with SLE. Lupus Sci Med 8(1). https:\/\/doi.org\/10.1136\/lupus-2021-000479","DOI":"10.1136\/lupus-2021-000479"},{"issue":"4","key":"5734_CR60","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","volume":"21","author":"JR Teijaro","year":"2021","unstructured":"Teijaro JR, Farber DL (2021) COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol 21(4):195\u2013197. https:\/\/doi.org\/10.1038\/s41577-021-00526-x","journal-title":"Nat Rev Immunol"},{"key":"5734_CR61","unstructured":"American College of Rheumatology COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases. https:\/\/www.rheumatology.org\/Portals\/0\/Files\/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf. Accessed 12 Dec 2023"},{"issue":"11","key":"5734_CR62","doi-asserted-by":"publisher","first-page":"e778","DOI":"10.1016\/S2665-9913(21)00222-8","volume":"3","author":"L Boekel","year":"2021","unstructured":"Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZLE, Kummer LY, Wolbink G (2021) Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol 3(11):e778\u2013e788. https:\/\/doi.org\/10.1016\/S2665-9913(21)00222-8","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"5734_CR63","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00296-021-04972-7","volume":"41","author":"LE Bartels","year":"2021","unstructured":"Bartels LE, Ammitzb\u00f8ll C, Andersen JB, Vils SR, Mistegaard CE, Johannsen AD, Troldborg A (2021) Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int 41(11):1925\u20131931. https:\/\/doi.org\/10.1007\/s00296-021-04972-7","journal-title":"Rheumatol Int"},{"issue":"1","key":"5734_CR64","doi-asserted-by":"publisher","first-page":"22777","DOI":"10.1038\/s41598-021-02321-z","volume":"11","author":"V Rotshild","year":"2021","unstructured":"Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I (2021) Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep 11(1):22777. https:\/\/doi.org\/10.1038\/s41598-021-02321-z","journal-title":"Sci Rep"},{"key":"5734_CR65","doi-asserted-by":"publisher","unstructured":"Ferri C, Ursini F, Gragnani L, Raimondo V, Giuggioli D, Foti R, Antonelli A (2021) Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients\u2019 subgroups. J Autoimmun 125:102744. https:\/\/doi.org\/10.1016\/j.jaut.2021.102744","DOI":"10.1016\/j.jaut.2021.102744"},{"issue":"11","key":"5734_CR66","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1016\/S2665-9913(21)00251-4","volume":"3","author":"MB Moor","year":"2021","unstructured":"Moor MB, Suter-Riniker F, Horn MP, Aeberli D, Amsler J, M\u00f6ller B, Sidler D (2021) Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol 3(11):e789\u2013e797. https:\/\/doi.org\/10.1016\/S2665-9913(21)00251-4","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"5734_CR67","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.7326\/m21-1757","volume":"174","author":"P Deepak","year":"2021","unstructured":"Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, Kim AHJ (2021) Effect of Immunosuppression on the Immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. Ann Intern Med 174(11):1572\u20131585. https:\/\/doi.org\/10.7326\/m21-1757","journal-title":"Ann Intern Med"},{"key":"5734_CR68","doi-asserted-by":"publisher","first-page":"740249","DOI":"10.3389\/fimmu.2021.740249","volume":"12","author":"A Picchianti-Diamanti","year":"2021","unstructured":"Picchianti-Diamanti A, Aiello A, Lagan\u00e0 B, Agrati C, Castilletti C, Meschi S, Goletti D (2021) Immunosuppressive therapies differently modulate humoral- and T-cell-specific responses to COVID-19 mRNA vaccine in rheumatoid arthritis patients. Front Immunol 12:740249. https:\/\/doi.org\/10.3389\/fimmu.2021.740249","journal-title":"Front Immunol"},{"issue":"7","key":"5734_CR69","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Sette A (2020) Targets of T Cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181(7):1489-1501.e1415. https:\/\/doi.org\/10.1016\/j.cell.2020.05.015","journal-title":"Cell"},{"issue":"10","key":"5734_CR70","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","volume":"20","author":"M Jeyanathan","year":"2020","unstructured":"Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z (2020) Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol 20(10):615\u2013632. https:\/\/doi.org\/10.1038\/s41577-020-00434-6","journal-title":"Nat Rev Immunol"},{"issue":"6576","key":"5734_CR71","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, Koup RA (2022) Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375(6576):43\u201350. https:\/\/doi.org\/10.1126\/science.abm3425","journal-title":"Science"},{"issue":"9","key":"5734_CR72","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00125-018-4660-9","volume":"61","author":"Tosur, M., Geyer, S. M., Rodriguez, H., Libman, I., Baidal, D. A., Redondo, M. J., & Type 1 Diabetes TrialNet Study Group","year":"2018","unstructured":"Tosur, M., Geyer, S. M., Rodriguez, H., Libman, I., Baidal, D. A., Redondo, M. J., & Type 1 Diabetes TrialNet Study Group (2018) Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk. Diabetologia 61(9):2043\u20132053. https:\/\/doi.org\/10.1007\/s00125-018-4660-9","journal-title":"Diabetologia"},{"key":"5734_CR73","doi-asserted-by":"publisher","unstructured":"Bundy N, De Jesus M, Lytle M et al (2023) Self-evidence-based digital care programme improves health-related quality of life in adults with a variety of autoimmune diseases and long COVID: a retrospective study. RMD Open 9:e003061. https:\/\/doi.org\/10.1136\/rmdopen-2023-003061","DOI":"10.1136\/rmdopen-2023-003061"},{"issue":"1","key":"5734_CR74","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/15476286.2022.2055923","volume":"19","author":"NZ Rouf","year":"2022","unstructured":"Rouf NZ, Biswas S, Tarannum N, Oishee LM, Muna MM (2022) Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases. RNA Biol 19(1):386\u2013410. https:\/\/doi.org\/10.1080\/15476286.2022.2055923","journal-title":"RNA Biol"},{"key":"5734_CR75","doi-asserted-by":"publisher","first-page":"e13083","DOI":"10.7717\/peerj.13083","volume":"10","author":"MZ Salleh","year":"2022","unstructured":"Salleh MZ, Norazmi MN, Deris ZZ (2022) Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. PeerJ 10:e13083. https:\/\/doi.org\/10.7717\/peerj.13083","journal-title":"PeerJ"},{"issue":"1","key":"5734_CR76","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s44178-023-00042-z","volume":"2","author":"N Kang","year":"2023","unstructured":"Kang N, Zhang S, Wang Y (2023) A personalized mRNA vaccine has exhibited potential in the treatment of pancreatic cancer. Holist Integ Oncol 2(1):18. https:\/\/doi.org\/10.1007\/s44178-023-00042-z","journal-title":"Holist Integ Oncol"},{"issue":"4","key":"5734_CR77","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discov 17(4):261\u2013279. https:\/\/doi.org\/10.1038\/nrd.2017.243","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"5734_CR78","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/ijms24032700","volume":"24","author":"V Gote","year":"2023","unstructured":"Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, Khan W (2023) A comprehensive review of mRNA vaccines. Int J Mol Sci 24(3):2700. https:\/\/doi.org\/10.3390\/ijms24032700","journal-title":"Int J Mol Sci"},{"key":"5734_CR79","doi-asserted-by":"publisher","unstructured":"Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, McGonagle D (2021) Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA\/DNA SARS-CoV-2 vaccination. Vaccines 9(5). https:\/\/doi.org\/10.3390\/vaccines9050435","DOI":"10.3390\/vaccines9050435"},{"key":"5734_CR80","doi-asserted-by":"publisher","first-page":"102743","DOI":"10.1016\/j.jaut.2021.102743","volume":"125","author":"AG Tzioufas","year":"2021","unstructured":"Tzioufas AG, Bakasis AD, Goules AV, Bitzogli K, Cinoku II, Chatzis LG, Moutsopoulos HM (2021) A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. J Autoimmun 125:102743. https:\/\/doi.org\/10.1016\/j.jaut.2021.102743","journal-title":"J Autoimmun"},{"key":"5734_CR81","doi-asserted-by":"publisher","unstructured":"Gasparotto M, Bindoli S, Padoan R, Cozzi G, Depascale R, Zanatta E, Iaccarino L (2022) New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort. Clin Exp Rheumatol https:\/\/doi.org\/10.55563\/clinexprheumatol\/vx44zn","DOI":"10.55563\/clinexprheumatol\/vx44zn"},{"key":"5734_CR82","doi-asserted-by":"publisher","unstructured":"De Stefano L, Balduzzi S, Bogliolo L, D\u2019Onofrio B, di Lernia M, Mauric E, Bugatti S (2022) Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immune-inflammatory arthritis treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol https:\/\/doi.org\/10.55563\/clinexprheumatol\/0ltj1i","DOI":"10.55563\/clinexprheumatol\/0ltj1i"},{"key":"5734_CR83","doi-asserted-by":"publisher","unstructured":"Rotondo C, Cantatore FP, Fornaro M, Colia R, Busto G, Rella V, Corrado A (2021) Preliminary data on post market safety profiles of COVID 19 vaccines in rheumatic diseases: assessments on various vaccines in use, different rheumatic disease subtypes, and immunosuppressive therapies: a two-centers study. Vaccines 9(7). https:\/\/doi.org\/10.3390\/vaccines9070730","DOI":"10.3390\/vaccines9070730"},{"issue":"3","key":"5734_CR84","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/1756-185x.14279","volume":"25","author":"F Haslak","year":"2022","unstructured":"Haslak F, Gunalp A, Cebi MN, Yildiz M, Adrovic A, Sahin S, Kasapcopur O (2022) Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: a single-center study. Int J Rheum Dis 25(3):353\u2013363. https:\/\/doi.org\/10.1111\/1756-185x.14279","journal-title":"Int J Rheum Dis"},{"key":"5734_CR85","doi-asserted-by":"publisher","unstructured":"Assawasaksakul T, Lertussavavivat T, Sathitratanacheewin S, Oudomying N, Vichaiwattana P, Wanlapakorn N, Kittanamongkolchai W (2022) Comparison of immunogenicity and safety of inactivated, adenovirus-vectored, and heterologous adenovirus-vectored\/mRNA vaccines in patients with systemic lupus erythematosus and rheumatoid arthritis: a prospective cohort study. Vaccines 10(6). https:\/\/doi.org\/10.3390\/vaccines10060853","DOI":"10.3390\/vaccines10060853"},{"key":"5734_CR86","doi-asserted-by":"publisher","unstructured":"Ramirez GA, Batani V, Moroni L, De Luca G, Pizzetti G, Sala S, Dagna L (2022) Cardiac safety of mRNA-based vaccines in patients with systemic lupus erythematosus and lupus-like disorders with a history of myocarditis. Pathogens 11(9). https:\/\/doi.org\/10.3390\/pathogens11091001","DOI":"10.3390\/pathogens11091001"},{"key":"5734_CR87","doi-asserted-by":"publisher","unstructured":"Gerosa M, Schioppo T, Argolini LM, Sciascia S, Ramirez GA, Moroni G, Caporali R (2022) The impact of anti-SARS-CoV-2 vaccine in patients with systemic lupus erythematosus: a multicentre cohort study. Vaccines 10(5). https:\/\/doi.org\/10.3390\/vaccines10050663","DOI":"10.3390\/vaccines10050663"},{"issue":"5","key":"5734_CR88","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s10067-021-05980-5","volume":"41","author":"E Zavala-Flores","year":"2022","unstructured":"Zavala-Flores E, Salcedo-Matienzo J, Quiroz-Alva A, Berrocal-Kasay A (2022) Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clin Rheumatol 41(5):1349\u20131357. https:\/\/doi.org\/10.1007\/s10067-021-05980-5","journal-title":"Clin Rheumatol"},{"issue":"3","key":"5734_CR89","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10238-021-00771-3","volume":"22","author":"D Firinu","year":"2022","unstructured":"Firinu D, Perra A, Campagna M, Littera R, Fenu G, Meloni F, Chessa L (2022) Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. Clin Exp Med 22(3):477\u2013485. https:\/\/doi.org\/10.1007\/s10238-021-00771-3","journal-title":"Clin Exp Med"},{"issue":"1","key":"5734_CR90","doi-asserted-by":"publisher","first-page":"e002265","DOI":"10.1136\/rmdopen-2022-002265","volume":"8","author":"GM Verstappen","year":"2022","unstructured":"Verstappen GM, de Wolff L, Arends S, Heiermann HM, van Sleen Y, Visser A, Terpstra JH, Diavatopoulos DA, van der Heiden M, Vissink A, van Baarle D, Kroese FGM, Bootsma H (2022) Immunogenicity and safety of COVID-19 vaccination in patients with primary Sj\u00f6gren\u2019s syndrome. RMD Open 8(1):e002265. https:\/\/doi.org\/10.1136\/rmdopen-2022-002265","journal-title":"RMD Open"},{"issue":"12","key":"5734_CR91","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1007\/s00296-021-05017-9","volume":"41","author":"JA Esquivel-Valerio","year":"2021","unstructured":"Esquivel-Valerio JA, Skinner-Taylor CM, Moreno-Arquieta IA, Cardenas-de la Garza JA, Garcia-Arellano G, Gonzalez-Garcia PL, Galarza-Delgado DA (2021) Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study. Rheumatol Int 41(12):2105\u20132108. https:\/\/doi.org\/10.1007\/s00296-021-05017-9","journal-title":"Rheumatol Int"},{"issue":"7","key":"5734_CR92","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1136\/annrheumdis-2021-221539","volume":"81","author":"C Papagoras","year":"2022","unstructured":"Papagoras C, Fragoulis GE, Zioga N, Simopoulou T, Deftereou K, Kalavri E, Sfikakis PP (2022) Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Ann Rheum Dis 81(7):1013\u20131016. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221539","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5734_CR93","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/acr2.11299","volume":"3","author":"C Ammitzb\u00f8ll","year":"2021","unstructured":"Ammitzb\u00f8ll C, Bartels LE, B\u00f8gh Andersen J, Risb\u00f8l Vils S, Elbaek Misteg\u00e5rd C, Dahl Johannsen A, Troldborg A (2021) Impaired antibody response to the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis. ACR Open Rheumatol 3(9):622\u2013628. https:\/\/doi.org\/10.1002\/acr2.11299","journal-title":"ACR Open Rheumatol"},{"issue":"10","key":"5734_CR94","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/annrheumdis-2021-220461","volume":"80","author":"D Simon","year":"2021","unstructured":"Simon D, Tascilar K, Fagni F, Kr\u00f6nke G, Kleyer A, Meder C, Schett G (2021) SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis 80(10):1312\u20131316. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220461","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"5734_CR95","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/annrheumdis-2021-220626","volume":"80","author":"M Prendecki","year":"2021","unstructured":"Prendecki M, Clarke C, Edwards H, McIntyre S, Mortimer P, Gleeson S, McAdoo SP (2021) Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis 80(10):1322\u20131329. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220626","journal-title":"Ann Rheum Dis"},{"key":"5734_CR96","doi-asserted-by":"publisher","unstructured":"Haberman RH, Herati RS, Simon D, Samanovic M, Blank RB, Tuen M, Scher JU (2021) Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. medRxiv. https:\/\/doi.org\/10.1101\/2021.05.11.21256917","DOI":"10.1101\/2021.05.11.21256917"},{"issue":"10","key":"5734_CR97","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1136\/annrheumdis-2021-220781","volume":"80","author":"D Mrak","year":"2021","unstructured":"Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, Bonelli M (2021) SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis 80(10):1345\u20131350. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220781","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5734_CR98","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s13311-021-01165-9","volume":"19","author":"F Capone","year":"2022","unstructured":"Capone F, Lucchini M, Ferraro E, Bianco A, Rossi M, Cicia A, Di Lazzaro V (2022) Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics 19(1):325\u2013333. https:\/\/doi.org\/10.1007\/s13311-021-01165-9","journal-title":"Neurotherapeutics"},{"issue":"6","key":"5734_CR99","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/art.42060","volume":"74","author":"AL Stefanski","year":"2022","unstructured":"Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, Karberg K, Szelinski F, Ritter J, D\u00f6rner T (2022) B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab. Arthritis Rheumatol 74(6):934\u2013947. https:\/\/doi.org\/10.1002\/art.42060","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"5734_CR100","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","volume":"27","author":"SA Apostolidis","year":"2021","unstructured":"Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, Bar-Or A (2021) Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 27(11):1990\u20132001. https:\/\/doi.org\/10.1038\/s41591-021-01507-2","journal-title":"Nat Med"},{"issue":"6","key":"5734_CR101","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1007\/s10787-022-01089-6","volume":"30","author":"S Bat\u0131bay","year":"2022","unstructured":"Bat\u0131bay S, Ulucak\u00f6y RK, G\u00fcnendi Z, Fidan I, Bozday\u0131 G, G\u00f6\u011f\u00fc\u015f FN (2022) Immunogenicity and safety of the CoronaVac and BNT162b2 Covid-19 vaccine in patients with inflammatory rheumatic diseases and healthy adults: comparison of different vaccines. Inflammopharmacology 30(6):2089\u20132096. https:\/\/doi.org\/10.1007\/s10787-022-01089-6","journal-title":"Inflammopharmacology"},{"key":"5734_CR102","doi-asserted-by":"publisher","unstructured":"Krasselt M, Wagner U, Nguyen P, Pietsch C, Boldt A, Baerwald C, Pierer M, Seifert O (2022) Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions. Rheumatology 61(SI2):SI180\u2013SI188. https:\/\/doi.org\/10.1093\/rheumatology\/keac089","DOI":"10.1093\/rheumatology\/keac089"},{"issue":"1","key":"5734_CR103","doi-asserted-by":"publisher","first-page":"e1037","DOI":"10.1093\/cid\/ciab954","volume":"75","author":"N Madelon","year":"2022","unstructured":"Madelon N, Lauper K, Breville G, Sabater Royo I, Goldstein R, Andrey DO, Grifoni A, Sette A, Kaiser L, Siegrist CA, Finckh A, Lalive PH, Didierlaurent AM, Eberhardt CS (2022) Robust T-Cell responses in anti-CD20-treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis 75(1):e1037\u2013e1045. https:\/\/doi.org\/10.1093\/cid\/ciab954","journal-title":"Clin Infect Dis"},{"issue":"6","key":"5734_CR104","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/03009742.2022.2062822","volume":"51","author":"HT Liao","year":"2022","unstructured":"Liao HT, Tung HY, Chou CT, Tsai HC, Yen YN, Tsai CY (2022) Immunogenicity of the mRNA-1273 and ChAdOx1 nCoV-19 vaccines in Asian patients with autoimmune rheumatic diseases under biologic and\/or conventional immunosuppressant treatments. Scand J Rheumatol 51(6):500\u2013505. https:\/\/doi.org\/10.1080\/03009742.2022.2062822","journal-title":"Scand J Rheumatol"},{"key":"5734_CR105","doi-asserted-by":"publisher","first-page":"846248","DOI":"10.3389\/fimmu.2022.846248","volume":"13","author":"GJ Szebeni","year":"2022","unstructured":"Szebeni GJ, G\u00e9mes N, Honfi D, Szab\u00f3 E, Neuperger P, Balog J\u00c1, Nagy LI, Szekanecz Z, Pusk\u00e1s LG, Toldi G, Balog A (2022) Humoral and cellular immunogenicity and safety of five different SARS-CoV-2 vaccines in patients with autoimmune rheumatic and musculoskeletal diseases in remission or with low disease activity and in healthy controls: a single center study. Front Immunol 13:846248. https:\/\/doi.org\/10.3389\/fimmu.2022.846248","journal-title":"Front Immunol"},{"issue":"2","key":"5734_CR106","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/ard-2022-222682","volume":"82","author":"F Kartnig","year":"2023","unstructured":"Kartnig F, Mrak D, Simader E, Tobudic S, Radner H, Mandl P, G\u00f6schl L, Hommer N, Mayer M, Hofer P, Hummel T, Deimel T, Ge\u00dfl I, Puchner A, Kerschbaumer A, Thalhammer R, Handisurya A, Kain R, Winkler S, Smolen JS, Bonelli M (2023) Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls. Ann Rheum Dis 82(2):292\u2013300. https:\/\/doi.org\/10.1136\/ard-2022-222682","journal-title":"Ann Rheum Dis"},{"key":"5734_CR107","doi-asserted-by":"publisher","first-page":"152177","DOI":"10.1016\/j.semarthrit.2023.152177","volume":"59","author":"SK Tedeschi","year":"2023","unstructured":"Tedeschi SK, Solomon DH, Chen Y, Ellrodt J, Whelan MG, Stratton J, Hayashi K, Whiteman NB, Chen L, Adejoorin I, Marks KE, Gomez-Rivas E, Rao DA, Jonsson AH, Wesemann DR (2023) Humoral and cellular immune responses in persons with rheumatoid arthritis after a third dose of mRNA COVID-19 vaccine. Semin Arthritis Rheum 59:152177. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152177","journal-title":"Semin Arthritis Rheum"},{"key":"5734_CR108","doi-asserted-by":"publisher","unstructured":"Le Moine C, Soyfoo MS, Mekkaoui L, Dahma H, Tant L (2023) Waning humoral immunity of SARS-CoV-2 vaccination in a rheumatoid arthritis cohort and the benefits of a vaccine booster dose. Clin Exp Rheumatol 41(1):82\u201387. https:\/\/doi.org\/10.55563\/clinexprheumatol\/ti3tvu","DOI":"10.55563\/clinexprheumatol\/ti3tvu"},{"key":"5734_CR109","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijid.2022.10.035","volume":"125","author":"C Farroni","year":"2022","unstructured":"Farroni C, Aiello A, Picchianti-Diamanti A, Lagan\u00e0 B, Petruccioli E, Agrati C, Garbuglia AR, Meschi S, Lapa D, Cuzzi G, Petrone L, Vanini V, Salmi A, Altera AMG, Repele F, Grassi G, Bettini A, Vita S, Mariano A, Damiani A, Goletti D (2022) Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: a prospective multicenter longitudinal study. Int J Infect Dis 125:195\u2013208. https:\/\/doi.org\/10.1016\/j.ijid.2022.10.035","journal-title":"Int J Infect Dis"},{"key":"5734_CR110","doi-asserted-by":"publisher","first-page":"1033804","DOI":"10.3389\/fimmu.2022.1033804","volume":"13","author":"J Wro\u0144ski","year":"2022","unstructured":"Wro\u0144ski J, Jaszczyk B, Roszkowski L, Felis-Giemza A, Bonek K, Kornatka A, Pleba\u0144czyk M, Burakowski T, Lisowska B, Kwiatkowska B, Ma\u015bli\u0144ski W, Wis\u0142owska M, Massalska M, Ciechomska M, Kuca-Warnawin E (2022) Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients. Front Immunol 13:1033804. https:\/\/doi.org\/10.3389\/fimmu.2022.1033804","journal-title":"Front Immunol"},{"key":"5734_CR111","doi-asserted-by":"publisher","unstructured":"Avouac J, Miceli-Richard C, Combier A, Steelandt A, Fogel O, Mariaggi AA, Meritet JF, Rozenberg F, Molto A, Allanore Y (2022) Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients. Rheumatology 61(SI2):SI163\u2013SI168. https:\/\/doi.org\/10.1093\/rheumatology\/keab815","DOI":"10.1093\/rheumatology\/keab815"},{"issue":"3","key":"5734_CR112","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3390\/vaccines11030666","volume":"11","author":"F Baroun","year":"2023","unstructured":"Baroun F, Albasri A, Abutiban F, Alhajeri H (2023) CVAPPS: a cross-sectional study of SARS-CoV-2 vaccine acceptance, perceptions, and post-vaccination side effects among rheumatic disease patients in Kuwait. Vaccines 11(3):666. https:\/\/doi.org\/10.3390\/vaccines11030666","journal-title":"Vaccines"},{"issue":"3","key":"5734_CR113","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3899\/jrheum.220475","volume":"50","author":"K Schultz","year":"2023","unstructured":"Schultz K, Jannat-Khah D, Spiera R (2023) B cell reconstitution is associated with COVID-19 booster vaccine responsiveness in patients previously seronegative treated with rituximab. J Rheumatol 50(3):420\u2013425. https:\/\/doi.org\/10.3899\/jrheum.220475","journal-title":"J Rheumatol"},{"key":"5734_CR114","doi-asserted-by":"publisher","first-page":"102996","DOI":"10.1016\/j.jaut.2023.102996","volume":"135","author":"A Ten Hagen","year":"2023","unstructured":"Ten Hagen A, Hermann S, Habermann E, Frommert LM, Arumahandi de Silva AN, Scholz V, Ghannam K, Klotsche J, Zernicke J, Alexander T, Burmester GR, Albach FN, Biesen R (2023) Improvement of humoral immunity by repeated dose-intensified COVID-19 vaccinations in primary non- to low-responders and B cell deficient rheumatic disease patients. J Autoimmun 135:102996. https:\/\/doi.org\/10.1016\/j.jaut.2023.102996","journal-title":"J Autoimmun"},{"issue":"7","key":"5734_CR115","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1093\/rheumatology\/keac666","volume":"62","author":"C Ammitzb\u00f8ll","year":"2023","unstructured":"Ammitzb\u00f8ll C, Kragh Thomsen M, B\u00f8gh Andersen J, Jensen JMB, From Hermansen ML, Dahl Johannsen A, Larsen ML, Mistegaard CE, Mikkelsen S, Szabados F, Vils SR, Erikstrup C, Hauge EM, Troldborg A (2023) Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders. Rheumatology 62(7):2544\u20132549. https:\/\/doi.org\/10.1093\/rheumatology\/keac666","journal-title":"Rheumatology"},{"issue":"1","key":"5734_CR116","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12916-023-02868-w","volume":"21","author":"F Filippini","year":"2023","unstructured":"Filippini F, Giacomelli M, Bazzani C, Fredi M, Semeraro P, Tomasi C, Franceschini F, Caruso A, Cavazzana I, Giagulli C (2023) Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response. BMC Med 21(1):210. https:\/\/doi.org\/10.1186\/s12916-023-02868-w","journal-title":"BMC Med"},{"issue":"19","key":"5734_CR117","doi-asserted-by":"publisher","first-page":"11411","DOI":"10.3390\/ijms231911411","volume":"23","author":"D Honfi","year":"2022","unstructured":"Honfi D, G\u00e9mes N, Szab\u00f3 E, Neuperger P, Balog J\u00c1, Nagy LI, Toldi G, Pusk\u00e1s LG, Szebeni GJ, Balog A (2022) Comparison of homologous and heterologous booster SARS-CoV-2 vaccination in autoimmune rheumatic and musculoskeletal patients. Int J Mol Sci 23(19):11411. https:\/\/doi.org\/10.3390\/ijms231911411","journal-title":"Int J Mol Sci"},{"key":"5734_CR118","doi-asserted-by":"publisher","unstructured":"Simoncelli E, Conticini E, Colafrancesco S, Gattamelata A, Spinelli FR, Garufi C, Truglia S, Grazzini S, Giardina F, Izzo R, Cantarini L, Frediani B, Conti F, Priori R (2023) Multicentre case-control study evaluating the safety of anti-SARS-CoV-2 vaccines in a cohort of patients with systemic vasculitis. Clin Exp Rheumatol 41(4):922\u2013927. https:\/\/doi.org\/10.55563\/clinexprheumatol\/if8nka","DOI":"10.55563\/clinexprheumatol\/if8nka"},{"issue":"14","key":"5734_CR119","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.3346\/jkms.2023.38.e109","volume":"38","author":"ES Kang","year":"2023","unstructured":"Kang ES, Oh JS, Lee EJ, Hong S, Ahn SM, Lee CK, Yoo B, Kim YG (2023) Anti-S1\/RBD-specific antibody formation after SARS-CoV-2 vaccination in elderly rheumatoid arthritis patients: single-center prospective observational study. J Korean Med Sci 38(14):e109. https:\/\/doi.org\/10.3346\/jkms.2023.38.e109","journal-title":"J Korean Med Sci"},{"issue":"6","key":"5734_CR120","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1093\/rheumatology\/keac574","volume":"62","author":"L Gumber","year":"2023","unstructured":"Gumber L, Gomez N, Hopkins G, Tucis D, Bartlett L, Ayling K, Vedhara K, Steers G, Chakravorty M, Rutter M, Jackson H, Tighe P, Ferraro A, Power S, Prad\u00e8re MJ, Onion D, Lanyon PC, Pearce FA, Fairclough L (2023) Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination. Rheumatology 62(6):2294\u20132303. https:\/\/doi.org\/10.1093\/rheumatology\/keac574","journal-title":"Rheumatology"},{"key":"5734_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1142\/S2661341723500013","volume":"23","author":"A Ting","year":"2023","unstructured":"Ting A, Chung HY, Chan S, Lam V (2023) Risk of exacerbation of rheumatic disease after COVID-19 vaccination. J Clin Rheumatol Immunol 23:1\u201311. https:\/\/doi.org\/10.1142\/S2661341723500013","journal-title":"J Clin Rheumatol Immunol"},{"key":"5734_CR122","doi-asserted-by":"publisher","unstructured":"Frodlund M, Nived P, Chatzidionysiou A, S\u00f6dergren A, Klingberg E, Bengtsson A, Hansson M, Olsson S, Pin E, Klareskog L, Kapetanovic MC (2023) The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA). Vaccine 41(20):3247\u20133257. https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.065","DOI":"10.1016\/j.vaccine.2023.03.065"},{"issue":"2","key":"5734_CR123","doi-asserted-by":"publisher","first-page":"e002998","DOI":"10.1136\/rmdopen-2023-002998","volume":"9","author":"R Hasseli","year":"2023","unstructured":"Hasseli R, Richter JG, Hoyer BF, Lorenz HM, Pfeil A, Regierer AC, Schmeiser T, Strangfeld A, Voll RE, Krause A, Reckert S, Gr\u00e4\u00dfler A, Saar P, Kapelle A, Backhaus M, Blank N, Henes J, Osiek S, Knothe A, Hoese G, COVID19-Rheuma.de collaborators (2023) Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases. RMD Open 9(2):e002998. https:\/\/doi.org\/10.1136\/rmdopen-2023-002998","journal-title":"RMD Open"},{"issue":"3","key":"5734_CR124","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3390\/vaccines11030537","volume":"11","author":"P Intapiboon","year":"2023","unstructured":"Intapiboon P, Pinpathomrat N, Juthong S, Uea-Areewongsa P, Ongarj J, Siripaitoon B (2023) Humoral immunogenicity of mRNA booster vaccination after heterologous CoronaVac-ChAdOx1 nCoV-19 or homologous ChAdOx1 nCoV-19 vaccination in patients with autoimmune rheumatic diseases: a preliminary report. Vaccines 11(3):537. https:\/\/doi.org\/10.3390\/vaccines11030537","journal-title":"Vaccines"},{"key":"5734_CR125","doi-asserted-by":"publisher","first-page":"1194821","DOI":"10.3389\/fped.2023.1194821","volume":"11","author":"B Lerkvaleekul","year":"2023","unstructured":"Lerkvaleekul B, Charuvanij S, Sukharomana M, Pirojsakul K, Kamolwatwong M, Vilaiyuk S (2023) Outcomes in children with rheumatic diseases following COVID-19 vaccination and infection: data from a large two-center cohort study in Thailand. Front Pediatr 11:1194821. https:\/\/doi.org\/10.3389\/fped.2023.1194821","journal-title":"Front Pediatr"},{"key":"5734_CR126","doi-asserted-by":"publisher","first-page":"1002168","DOI":"10.3389\/fonc.2022.1002168","volume":"12","author":"S Di Cosimo","year":"2022","unstructured":"Di Cosimo S, Lupo-Stanghellini MT, Costantini M, Mantegazza R, Ciceri F, Salvarani C, Zinzani PL, Mantovani A, Ciliberto G, Uccelli A, Baldanti F, Apolone G, Delcuratolo S, Morrone A, Locatelli F, Agrati C, Silvestris N (2022) Safety of third dose of COVID-19 vaccination in frail patients: results from the prospective Italian VAX4FRAIL study. Front Oncol 12:1002168. https:\/\/doi.org\/10.3389\/fonc.2022.1002168","journal-title":"Front Oncol"},{"issue":"13","key":"5734_CR127","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.2169\/internalmedicine.9223-21","volume":"61","author":"K Sugihara","year":"2022","unstructured":"Sugihara K, Wakiya R, Shimada H, Kameda T, Nakashima S, Kato M, Miyagi T, Mizusaki M, Mino R, Nomura Y, Inoo M, Kadowaki N, Dobashi H (2022) Immunogenicity against the BNT162b2 mRNA COVID-19 vaccine in rheumatic disease patients receiving immunosuppressive therapy. Intern Med 61(13):1953\u20131958. https:\/\/doi.org\/10.2169\/internalmedicine.9223-21","journal-title":"Intern Med"},{"issue":"6","key":"5734_CR128","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s10067-023-06512-z","volume":"42","author":"MG Whelan","year":"2023","unstructured":"Whelan MG, Santacroce L, Masto L, Qian G, Kowalski E, Vanni K, Kanjilal S, Weinblatt ME, Sparks JA, Tedeschi SK (2023) Predictors of low spike antibody response in patients with systemic rheumatic disease after an initial course of COVID-19 vaccination. Clin Rheumatol 42(6):1695\u20131700. https:\/\/doi.org\/10.1007\/s10067-023-06512-z","journal-title":"Clin Rheumatol"},{"key":"5734_CR129","doi-asserted-by":"publisher","unstructured":"Rose E, Magliulo D, Kyttaris VC (2022) Seroconversion among rituximab-treated patients following SARS-CoV-2 vaccine supplemental dose. Clin Immunol 245:109144. https:\/\/doi.org\/10.1016\/j.clim.2022.109144","DOI":"10.1016\/j.clim.2022.109144"},{"issue":"6","key":"5734_CR130","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3899\/jrheum.211152","volume":"49","author":"A Troldborg","year":"2022","unstructured":"Troldborg A, Thomsen MK, Bartels LE, Andersen JB, Vils SR, Mistegaard CE, Johannsen AD, Hermansen MF, Mikkelsen S, Erikstrup C, Hauge EM, Ammitzb\u00f8ll C (2022) Time since rituximab treatment is essential for developing a humoral response to COVID-19 mRNA vaccines in patients with rheumatic diseases. J Rheumatol 49(6):644\u2013649. https:\/\/doi.org\/10.3899\/jrheum.211152","journal-title":"J Rheumatol"},{"key":"5734_CR131","doi-asserted-by":"publisher","unstructured":"Jinich S, Schultz K, Jannat-Khah D, Spiera R (2022) B cell reconstitution is strongly associated with COVID-19 vaccine responsiveness in rheumatic disease patients who received treatment with rituximab. Arthritis Rheumatol 74(5):776\u2013782. https:\/\/doi.org\/10.1002\/art.42034","DOI":"10.1002\/art.42034"},{"issue":"5","key":"5734_CR132","doi-asserted-by":"publisher","first-page":"735.e5","DOI":"10.1016\/j.cmi.2022.02.002","volume":"28","author":"E Saiag","year":"2022","unstructured":"Saiag E, Grupper A, Avivi I, Elkayam O, Ram R, Herishanu Y, Cohen Y, Perry C, Furer V, Katchman H, Rabinowich L, Ben-Yehoyada M, Halperin T, Baruch R, Goldshmidt H, Hagin D, Ben-Ami R, Sprecher E, Bomze D (2022) The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients. Clin Microbiol Infect 28(5):735.e5-735.e8. https:\/\/doi.org\/10.1016\/j.cmi.2022.02.002","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"5734_CR133","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/cei\/uxab018","volume":"207","author":"AM Shields","year":"2022","unstructured":"Shields AM, Venkatachalam S, Shafeek S, Paneesha S, Ford M, Sheeran T, Kelly M, Qureshi I, Salhan B, Karim F, De Silva N, Stones J, Lee S, Khawaja J, Kaudlay PK, Whitmill R, Kakepoto GN, Parry HM, Moss P, Faustini SE, Basu S (2022) SARS-CoV-2 vaccine responses following CD20-depletion treatment in patients with haematological and rheumatological disease: a West Midlands Research Consortium study. Clin Exp Immunol 207(1):3\u201310. https:\/\/doi.org\/10.1093\/cei\/uxab018","journal-title":"Clin Exp Immunol"},{"key":"5734_CR134","doi-asserted-by":"publisher","unstructured":"Habermann E, Gieselmann L, Tober-Lau P, Klotsche J, Albach FN, Ten Hagen A, Zernicke J, Ahmadov E, Arumahandi de Silva AN, Frommert LM, Kurth F, Sander LE, Burmester GR, Klein F, Biesen R (2022) Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination. RMD Open 8(2):e002639. https:\/\/doi.org\/10.1136\/rmdopen-2022-002639","DOI":"10.1136\/rmdopen-2022-002639"},{"issue":"32","key":"5734_CR135","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.3346\/jkms.2023.38.e247","volume":"38","author":"JW Kim","year":"2023","unstructured":"Kim JW, Jung JY, Suh CH, Ye YM, Kim HA (2023) Effects of COVID-19 and influenza vaccination on rheumatic diseases: results from a survey of patient-reported outcomes after vaccination. J Korean Med Sci 38(32):e247. https:\/\/doi.org\/10.3346\/jkms.2023.38.e247","journal-title":"J Korean Med Sci"},{"key":"5734_CR136","doi-asserted-by":"publisher","first-page":"1187880","DOI":"10.3389\/fimmu.2023.1187880","volume":"14","author":"C Chu","year":"2023","unstructured":"Chu C, Sch\u00f6nbrunn A, Fischer D, Liu Y, Hocher JG, Weinerth J, Klemm K, von Baehr V, Kr\u00e4mer BK, Elitok S, Hocher B (2023) Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients. Front Immunol 14:1187880. https:\/\/doi.org\/10.3389\/fimmu.2023.1187880","journal-title":"Front Immunol"},{"issue":"1","key":"5734_CR137","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/rheumatology\/keac301","volume":"62","author":"NE Aikawa","year":"2022","unstructured":"Aikawa NE, Kupa LVK, Silva CA, Saad CGS, Pasoto SG, Yuki EFN, Fusco SRG, Shinjo SK, Andrade DCO, Sampaio-Barros PD, Pereira RMR, Chasin ACS, Shimabuco AY, Luppino-Assad AP, Leon EP, Lopes MH, Antonangelo L, Medeiros-Ribeiro AC, Bonfa E (2022) Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine. Rheumatology 62(1):480\u2013485. https:\/\/doi.org\/10.1093\/rheumatology\/keac301","journal-title":"Rheumatology"},{"issue":"2","key":"5734_CR138","doi-asserted-by":"publisher","first-page":"e003022","DOI":"10.1136\/rmdopen-2023-003022","volume":"9","author":"F Ursini","year":"2023","unstructured":"Ursini F, Ruscitti P, Addimanda O, Foti R, Raimondo V, Murdaca G, Caira V, Pigatto E, Cuomo G, Lo Gullo A, Cavazzana I, Campochiaro C, Naclerio C, De Angelis R, Ciaffi J, Mancarella L, Brusi V, Marchetti E, Motta F, Visentini M, Ferri C (2023) Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group. RMD Open 9(2):e003022. https:\/\/doi.org\/10.1136\/rmdopen-2023-003022","journal-title":"RMD Open"},{"issue":"5","key":"5734_CR139","doi-asserted-by":"publisher","first-page":"e071397","DOI":"10.1136\/bmjopen-2022-071397","volume":"13","author":"CA Hitchon","year":"2023","unstructured":"Hitchon CA, Mesa C, Bernstein CN, Marrie RA, Card C, O\u2019Brien SF, Kim J (2023) Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-centre prospective cohort study. BMJ Open 13(5):e071397. https:\/\/doi.org\/10.1136\/bmjopen-2022-071397","journal-title":"BMJ Open"},{"issue":"6","key":"5734_CR140","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s12026-021-09226-z","volume":"69","author":"G Malipiero","year":"2021","unstructured":"Malipiero G, Moratto A, Infantino M, D\u2019Agaro P, Piscianz E, Manfredi M, Grossi V, Benvenuti E, Bulgaresi M, Benucci M, Villalta D (2021) Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease. Immunol Res 69(6):576\u2013583. https:\/\/doi.org\/10.1007\/s12026-021-09226-z","journal-title":"Immunol Res"},{"issue":"12","key":"5734_CR141","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/acr2.11336","volume":"3","author":"R Bixio","year":"2021","unstructured":"Bixio R, Bertelle D, Masia M, Pistillo F, Carletto A, Rossini M (2021) Incidence of disease flare after BNT162b2 coronavirus disease 2019 vaccination in patients with rheumatoid arthritis in remission. ACR Open Rheumatol 3(12):832\u2013833. https:\/\/doi.org\/10.1002\/acr2.11336","journal-title":"ACR Open Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05734-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05734-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05734-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T16:07:19Z","timestamp":1733328439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05734-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":141,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5734"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05734-x","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}